Zylox-Tonbridge Medical Technology Co., Ltd. (02190) published a Next Day Disclosure Return dated 3 November 2025, highlighting changes in its issued and treasury shares. The opening balance as of 31 October 2025 showed 315,804,613 issued shares (excluding treasury shares) and 6,596,131 treasury shares. On 3 November 2025, 50,000 shares were repurchased at a price of HKD 23.976 per share, amounting to approximately 0.0155% of the issued shares before the event. Following this, the closing balance amounted to 315,754,613 issued shares (excluding treasury shares) and 6,646,131 treasury shares, with total issued shares unchanged at 322,400,744.

According to the repurchase report, 50,000 H shares were acquired on the Exchange on 3 November 2025, at prices ranging from HKD 23.34 to HKD 24.12, for an aggregate consideration of HKD 1,198,800. All repurchased shares are held as treasury shares, in line with a repurchase mandate dated 30 May 2025, which authorized up to 31,958,111 shares for repurchase. The report also notes a mandatory one-month moratorium prohibiting further share issues or treasury share disposals until 3 December 2025. The announcement confirms that all procedures fulfilled relevant listing rules and regulatory requirements, and all necessary documents have been duly filed.